Müllerian inhibiting substance type 2 receptor (MISIIR)-specific CAR T cells for the treatment of ovarian cancer and other gynecologic malignancies

Patent metadata

Field	Value
Publication number	US-12559563-B2
Application number	US-202017603539-A
Country	US
Kind code	B2
Filing date	Apr 14, 2020
Priority date	Apr 15, 2019
Publication date	Feb 24, 2026
Grant date	Feb 24, 2026

Abstract

The present disclosure provides modified immune cells or precursors thereof (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity for Müllerian inhibiting substance type 2 receptor (MISIIR). Compositions and methods of treatment of diseases and disorders, such as ovarian and other gynecologic cancers, are also provided. Additionally provided herein are modified immune cells or precursor cells thereof comprising a nucleic acid encoding a CAR having affinity for Müllerian inhibiting substance type 2 receptor (MISIIR).

First claim

What is claimed:

1 . A modified immune cell or precursor cell thereof, comprising:
a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain having affinity for Müllerian inhibiting substance type 2 receptor (MISIIR), a transmembrane domain, and an intracellular domain, wherein the CAR comprises the amino acid sequence set forth in SEQ ID NO: 2, and/or is encoded by the nucleotide sequence set forth in SEQ ID NO: 1.

2 . The modified immune cell or precursor cell of claim 1 , wherein:
(a) the cell is an autologous cell; and/or (b) the cell is isolated from a human subject; and/or (c) the cell is a modified T cell.

3 . A method of treating cancer in a subject in need thereof, the method comprising administering to the subject the modified immune or precursor cell of claim 1 .

4 . A method of treating a cancer in a subject in need thereof, comprising administering to the subject a modified T cell comprising: a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain having affinity for Mullerian inhibiting substance type 2 receptor (MISIIR), a transmembrane domain, and an intracellular domain, wherein the CAR comprises the amino acid sequence set forth in SEQ ID NO: 2, and/or is encoded by the nucleotide sequence set forth in SEQ ID NO: 1.

5 . The method of claim 4 , wherein,
(a) the cancer is selected from the group consisting of ovarian cancer, endometrial cancer, uterine sarcoma, cervical carcinoma, breast cancer, lung cancer, prostate cancer, ocular melanoma, a MISIIR-expressing tumor, and ovarian cancer; and/or (b) the modified T cell is human; and/or (c) the modified T cell is autologous; and/or (d) the subject is human.

Assignees

• Univ Pennsylvania

Inventors

• Powell Daniel J
• Rodriguez-Garcia Alba

Classifications

• A61K40/4211

  CD19 or B4 · CPC title

• A61K40/4202

  Receptors, cell surface antigens or cell surface determinants · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/59

  Reproductive system, e.g. uterus, ovaries, cervix or testes · CPC title